Outcomes for patients with RAS-amplified metastatic colorectal cancer treated with anti-EGFR therapy
| Case . | Cohort . | Age, years . | Primary tumor location . | Amplified RAS gene . | RAS CN . | Prior OX or IRI . | Anti-EGFR therapy (line) . | Best response . | TTD, months . |
|---|---|---|---|---|---|---|---|---|---|
| 1 | COH | 51 | Left | KRAS | 13 | NA | FOLFIRI Pmab (first) | SD | 4 |
| 2 | COH | 51 | Right | KRAS | 20 | OX and IRI | FOLFIRI Pmab (third) | PD | 2 |
| 3 | COH | 48 | Left | KRAS | 25 | OX and IRI | IRI Cmab (second) | SD | 7 |
| 4 | COH | 31 | Left | KRAS | 29 | IRI | CAP Cmab (third) | PD | 2.5 |
| 5 | COH | 51 | Left | KRAS | 30 | OX and IRI | FOLFIRI Pmab (third) | PD | 2.5 |
| 6 | COH | 35 | Left | KRAS | 54 | OX and IRI | IRI Pmab (fourth) | PD | 0.5 |
| 7 | CGDB | 73 | NA | NRAS | 9 | OX and IRI | FOLFIRI Cmab (fourth) | NA | 23 |
| 8 | CGDB | 60 | Right | KRAS | 10 | OX | FOLFIRI Pmab (second) | NA | 2.5 |
| 9 | CGDB | 46 | Left | KRAS | 26 | IRI | FOLFIRI Cmab (second) | NA | 22 |
| 10 | CGDB | 75 | Left | KRAS | 28 | IRI | FOLFIRI Pmab (second) | NA | 3.9 |
| 11 | CGDB | 48 | Left | KRAS | 36 | OX and IRI | Pmab (fourth) | NA | 0.46 |
| 12 | CGDB | 44 | Left | KRAS | 44 | OX | FOLFIRI Pmab (second) | NA | 1.4 |
| 13 | CGDB | 31 | Left | KRAS | 47 | none | FOLFIRI Cmab (first) | NA | 3.5 |
| 14 | CGDB | 46 | Left | KRAS | 54 | OX and IRI | CAP IRI Pmab (third) | NA | 9.4 |
| 15 | CGDB | 46 | Left | KRAS | 62 | none | CAP OX Cmab (first) | NA | 4.7 |
| Case . | Cohort . | Age, years . | Primary tumor location . | Amplified RAS gene . | RAS CN . | Prior OX or IRI . | Anti-EGFR therapy (line) . | Best response . | TTD, months . |
|---|---|---|---|---|---|---|---|---|---|
| 1 | COH | 51 | Left | KRAS | 13 | NA | FOLFIRI Pmab (first) | SD | 4 |
| 2 | COH | 51 | Right | KRAS | 20 | OX and IRI | FOLFIRI Pmab (third) | PD | 2 |
| 3 | COH | 48 | Left | KRAS | 25 | OX and IRI | IRI Cmab (second) | SD | 7 |
| 4 | COH | 31 | Left | KRAS | 29 | IRI | CAP Cmab (third) | PD | 2.5 |
| 5 | COH | 51 | Left | KRAS | 30 | OX and IRI | FOLFIRI Pmab (third) | PD | 2.5 |
| 6 | COH | 35 | Left | KRAS | 54 | OX and IRI | IRI Pmab (fourth) | PD | 0.5 |
| 7 | CGDB | 73 | NA | NRAS | 9 | OX and IRI | FOLFIRI Cmab (fourth) | NA | 23 |
| 8 | CGDB | 60 | Right | KRAS | 10 | OX | FOLFIRI Pmab (second) | NA | 2.5 |
| 9 | CGDB | 46 | Left | KRAS | 26 | IRI | FOLFIRI Cmab (second) | NA | 22 |
| 10 | CGDB | 75 | Left | KRAS | 28 | IRI | FOLFIRI Pmab (second) | NA | 3.9 |
| 11 | CGDB | 48 | Left | KRAS | 36 | OX and IRI | Pmab (fourth) | NA | 0.46 |
| 12 | CGDB | 44 | Left | KRAS | 44 | OX | FOLFIRI Pmab (second) | NA | 1.4 |
| 13 | CGDB | 31 | Left | KRAS | 47 | none | FOLFIRI Cmab (first) | NA | 3.5 |
| 14 | CGDB | 46 | Left | KRAS | 54 | OX and IRI | CAP IRI Pmab (third) | NA | 9.4 |
| 15 | CGDB | 46 | Left | KRAS | 62 | none | CAP OX Cmab (first) | NA | 4.7 |
For COH cases, TTD was equivalent to progression-free survival.
Abbreviations: CAP, capecitabine; CGDB, clinicogenomic database; Cmab, cetuximab; CN, copy number; COH, City of Hope; EGFR, epidermal growth factor receptor; FOLFIRI, folinic acid, fluorouracil and irinotecan; IRI, irinotecan; NA, not available; OX, oxaliplatin, PD, progressive disease; Pmab, panitumumab; SD, stable disease; TTD, time to treatment discontinuation.
Outcomes for patients with RAS-amplified metastatic colorectal cancer treated with anti-EGFR therapy
| Case . | Cohort . | Age, years . | Primary tumor location . | Amplified RAS gene . | RAS CN . | Prior OX or IRI . | Anti-EGFR therapy (line) . | Best response . | TTD, months . |
|---|---|---|---|---|---|---|---|---|---|
| 1 | COH | 51 | Left | KRAS | 13 | NA | FOLFIRI Pmab (first) | SD | 4 |
| 2 | COH | 51 | Right | KRAS | 20 | OX and IRI | FOLFIRI Pmab (third) | PD | 2 |
| 3 | COH | 48 | Left | KRAS | 25 | OX and IRI | IRI Cmab (second) | SD | 7 |
| 4 | COH | 31 | Left | KRAS | 29 | IRI | CAP Cmab (third) | PD | 2.5 |
| 5 | COH | 51 | Left | KRAS | 30 | OX and IRI | FOLFIRI Pmab (third) | PD | 2.5 |
| 6 | COH | 35 | Left | KRAS | 54 | OX and IRI | IRI Pmab (fourth) | PD | 0.5 |
| 7 | CGDB | 73 | NA | NRAS | 9 | OX and IRI | FOLFIRI Cmab (fourth) | NA | 23 |
| 8 | CGDB | 60 | Right | KRAS | 10 | OX | FOLFIRI Pmab (second) | NA | 2.5 |
| 9 | CGDB | 46 | Left | KRAS | 26 | IRI | FOLFIRI Cmab (second) | NA | 22 |
| 10 | CGDB | 75 | Left | KRAS | 28 | IRI | FOLFIRI Pmab (second) | NA | 3.9 |
| 11 | CGDB | 48 | Left | KRAS | 36 | OX and IRI | Pmab (fourth) | NA | 0.46 |
| 12 | CGDB | 44 | Left | KRAS | 44 | OX | FOLFIRI Pmab (second) | NA | 1.4 |
| 13 | CGDB | 31 | Left | KRAS | 47 | none | FOLFIRI Cmab (first) | NA | 3.5 |
| 14 | CGDB | 46 | Left | KRAS | 54 | OX and IRI | CAP IRI Pmab (third) | NA | 9.4 |
| 15 | CGDB | 46 | Left | KRAS | 62 | none | CAP OX Cmab (first) | NA | 4.7 |
| Case . | Cohort . | Age, years . | Primary tumor location . | Amplified RAS gene . | RAS CN . | Prior OX or IRI . | Anti-EGFR therapy (line) . | Best response . | TTD, months . |
|---|---|---|---|---|---|---|---|---|---|
| 1 | COH | 51 | Left | KRAS | 13 | NA | FOLFIRI Pmab (first) | SD | 4 |
| 2 | COH | 51 | Right | KRAS | 20 | OX and IRI | FOLFIRI Pmab (third) | PD | 2 |
| 3 | COH | 48 | Left | KRAS | 25 | OX and IRI | IRI Cmab (second) | SD | 7 |
| 4 | COH | 31 | Left | KRAS | 29 | IRI | CAP Cmab (third) | PD | 2.5 |
| 5 | COH | 51 | Left | KRAS | 30 | OX and IRI | FOLFIRI Pmab (third) | PD | 2.5 |
| 6 | COH | 35 | Left | KRAS | 54 | OX and IRI | IRI Pmab (fourth) | PD | 0.5 |
| 7 | CGDB | 73 | NA | NRAS | 9 | OX and IRI | FOLFIRI Cmab (fourth) | NA | 23 |
| 8 | CGDB | 60 | Right | KRAS | 10 | OX | FOLFIRI Pmab (second) | NA | 2.5 |
| 9 | CGDB | 46 | Left | KRAS | 26 | IRI | FOLFIRI Cmab (second) | NA | 22 |
| 10 | CGDB | 75 | Left | KRAS | 28 | IRI | FOLFIRI Pmab (second) | NA | 3.9 |
| 11 | CGDB | 48 | Left | KRAS | 36 | OX and IRI | Pmab (fourth) | NA | 0.46 |
| 12 | CGDB | 44 | Left | KRAS | 44 | OX | FOLFIRI Pmab (second) | NA | 1.4 |
| 13 | CGDB | 31 | Left | KRAS | 47 | none | FOLFIRI Cmab (first) | NA | 3.5 |
| 14 | CGDB | 46 | Left | KRAS | 54 | OX and IRI | CAP IRI Pmab (third) | NA | 9.4 |
| 15 | CGDB | 46 | Left | KRAS | 62 | none | CAP OX Cmab (first) | NA | 4.7 |
For COH cases, TTD was equivalent to progression-free survival.
Abbreviations: CAP, capecitabine; CGDB, clinicogenomic database; Cmab, cetuximab; CN, copy number; COH, City of Hope; EGFR, epidermal growth factor receptor; FOLFIRI, folinic acid, fluorouracil and irinotecan; IRI, irinotecan; NA, not available; OX, oxaliplatin, PD, progressive disease; Pmab, panitumumab; SD, stable disease; TTD, time to treatment discontinuation.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
